Cingulate Inc. (CING)
NASDAQ: CING
· Real-Time Price · USD
3.90
0.11 (2.90%)
At close: Sep 05, 2025, 3:59 PM
3.97
1.79%
After-hours: Sep 05, 2025, 05:15 PM EDT
Company Description
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder.
The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders.
It also focuses on developing CTx-2103 for the treatment of anxiety disorders.
The company was founded in 2012 and is headquartered in Kansas City, Kansas.
Cingulate Inc.
| Country | United States |
| IPO Date | Dec 8, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13 |
| CEO | Shane J. Schaffer |
Contact Details
Address: 1901 West 47th Place Kansas City, Kansas United States | |
| Website | https://www.cingulate.com |
Stock Details
| Ticker Symbol | CING |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001862150 |
| CUSIP Number | 17248W105 |
| ISIN Number | US17248W3034 |
| Employer ID | 86-3825535 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Shane J. Schaffer Pharm.D. | Co-Founder, Chief Executive Officer & Chairman of the Board |
| Dr. Laurie A. Myers M.B.A., Ph.D. | Executive Vice President & Chief Operating Officer |
| Dr. Matthew N. Brams M.D. | Co-Founder, Executive Vice President & Chief Medical Officer |
| Dr. Raul R. Silva M.D. | Co-Founder, Executive Vice President & Chief Science Officer |
| Thomas Dalton | Vice President of Investor & Public Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 28, 2025 | 8-K | Current Report |
| Aug 19, 2025 | 10-Q | Quarterly Report |
| Aug 19, 2025 | 8-K | Current Report |
| Aug 15, 2025 | DEF 14A | Filing |
| Aug 15, 2025 | NT 10-Q | Filing |
| Aug 15, 2025 | 8-K | Current Report |
| Aug 08, 2025 | 8-K | Current Report |
| Aug 06, 2025 | 8-K | Current Report |
| Aug 05, 2025 | PRE 14A | Filing |
| Jul 30, 2025 | 424B3 | Filing |